The U.S. Supreme Court decided Wyeth v. Levine March 4, which rejected the federal pre-emption defense to failure to warn claims against pharmaceutical manufacturers. The release of the court’s decision in one of the most highly anticipated cases of the term created a buzz both inside and outside of the legal community. Bloggers commented about it, the mainstream media wrote about it and litigators across the country scrambled to get a copy of the court’s opinion.
Since then, much has been written about the decision and its implications for patient safety, public health and the future of drug regulation in this country. Much has also been written about the future of federal pre-emption post- Wyeth .
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
